Denovo Biopharma Acquires Global Rights to Experimental Alzheimer’s Drug

With the multiple failures in targeting amyloid plaque in the treatment of Alzheimer’s disease, San Diego-based Denovo Biopharma is taking a different approach by targeting the Alpha2C adrenoceptor.